Published by Chapman and Hall/CRC (edition 1), 2021
ISBN 10: 1032242647 ISBN 13: 9781032242644
Language: English
Seller: BooksRun, Philadelphia, PA, U.S.A.
Paperback. Condition: Good. 1. It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience.
Published by Chapman and Hall/CRC, 2021
ISBN 10: 1032242647 ISBN 13: 9781032242644
Language: English
Seller: Books From California, Simi Valley, CA, U.S.A.
paperback. Condition: Fine.
Hardcover. Condition: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less 1.35.
Published by Taylor & Francis Ltd, 2021
ISBN 10: 1032242647 ISBN 13: 9781032242644
Language: English
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
US$ 74.35
Convert currencyQuantity: 1 available
Add to basketPaperback / softback. Condition: New. New copy - Usually dispatched within 4 working days.
US$ 71.45
Convert currencyQuantity: Over 20 available
Add to basketCondition: New. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.
US$ 149.28
Convert currencyQuantity: Over 20 available
Add to basketCondition: New.
Seller: Lucky's Textbooks, Dallas, TX, U.S.A.
US$ 147.94
Convert currencyQuantity: Over 20 available
Add to basketCondition: New.
US$ 87.63
Convert currencyQuantity: 2 available
Add to basketTaschenbuch. Condition: Neu. Neuware - This book is the first to focus on Bayesian phase I-II clinical trials. It describes many problems with the conventional phase I-phase II paradigm and covers a large number of modern Bayesian phase I-II clinical trial designs.
Condition: New.
US$ 156.10
Convert currencyQuantity: 3 available
Add to basketCondition: New.
Seller: California Books, Miami, FL, U.S.A.
Condition: New.
Published by Taylor & Francis Inc, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Language: English
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
US$ 151.31
Convert currencyQuantity: 1 available
Add to basketHardback. Condition: New. New copy - Usually dispatched within 4 working days. 652.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 168.01
Convert currencyQuantity: Over 20 available
Add to basketCondition: New. In.
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
US$ 168.00
Convert currencyQuantity: Over 20 available
Add to basketCondition: New.
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
US$ 234.96
Convert currencyQuantity: Over 20 available
Add to basketCondition: As New. Unread book in perfect condition.
Published by Chapman and Hall/CRC, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Language: English
Seller: Mispah books, Redhill, SURRE, United Kingdom
US$ 223.98
Convert currencyQuantity: 1 available
Add to basketHardcover. Condition: Like New. Like New. book.
US$ 254.08
Convert currencyQuantity: Over 20 available
Add to basketCondition: As New. Unread book in perfect condition.
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
HRD. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
US$ 156.37
Convert currencyQuantity: 2 available
Add to basketBuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 324 pp. Englisch.
Seller: Biblios, Frankfurt am main, HESSE, Germany
US$ 175.84
Convert currencyQuantity: 4 available
Add to basketCondition: New. PRINT ON DEMAND.
Seller: moluna, Greven, Germany
US$ 142.82
Convert currencyQuantity: Over 20 available
Add to basketCondition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.
Published by Taylor & Francis Inc, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Language: English
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
US$ 188.79
Convert currencyQuantity: Over 20 available
Add to basketHardback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.
Published by Chapman And Hall/CRC, 2016
ISBN 10: 1498709559 ISBN 13: 9781498709552
Language: English
Seller: AHA-BUCH GmbH, Einbeck, Germany
US$ 173.93
Convert currencyQuantity: 1 available
Add to basketBuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.